The pilot study, sponsored by the Hospital for Special Surgery in New York, aimed to explore the safety and efficacy of rTMS in treating depression symptoms in ALS patients. Despite the promising therapeutic potential of rTMS for mood disorders, the trial was terminated due to failure to meet enrollment targets, indicating potential challenges in patient recruitment for neurodegenerative conditions. The market for ALS therapies is competitive, with a growing focus on non-invasive treatment modalities. Companies developing rTMS devices may find opportunities in expanding indications for use, particularly in neurodegenerative disorders. However, the termination of this trial may raise concerns regarding the viability of rTMS as a treatment for depression in ALS, necessitating further investigation into patient engagement and recruitment strategies.